HC Wainwright Issues Positive Forecast for Humacyte Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Humacyte to ($0.37) from ($0.50) and projects EPS will turn positive by FY2029 ($0.10) and reach $0.38 in FY2030.
• Analysts are mixed but the consensus rating is a Moderate Buy with a $7.71 price target, even though Humacyte is trading around $0.59 with a market cap of $110.85 million.
• Humacyte's latest quarter matched EPS estimates at (‑$0.13) but missed revenue ($0.47M vs. $1.35M) and shows extreme negative profitability (net margin -1,998.87%, ROE -990.48%), indicating continued losses.

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Analysts at HC Wainwright increased their FY2026 earnings estimates for shares of Humacyte in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.37) per share for the year, up from their prior estimate of ($0.50). The consensus estimate for Humacyte's current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Humacyte's FY2027 earnings at ($0.27) EPS, FY2028 earnings at ($0.06) EPS, FY2029 earnings at $0.10 EPS and FY2030 earnings at $0.38 EPS.

Several other brokerages also recently weighed in on HUMA. Wall Street Zen downgraded Humacyte from a "hold" rating to a "sell" rating in a report on Sunday, December 21st. Weiss Ratings restated a "sell (d-)" rating on shares of Humacyte in a report on Monday, December 29th. Benchmark cut their price objective on Humacyte from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, January 21st. BTIG Research reduced their target price on Humacyte from $6.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday, March 27th. Finally, D. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of Humacyte in a research note on Friday, March 27th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.71.

Humacyte Stock Down 2.4%

Shares of NASDAQ:HUMA opened at $0.59 on Thursday. The firm has a market capitalization of $110.85 million, a PE ratio of -2.96 and a beta of 2.11. The business has a 50 day simple moving average of $1.02 and a two-hundred day simple moving average of $1.26. Humacyte has a 1 year low of $0.55 and a 1 year high of $2.93. The company has a debt-to-equity ratio of 20.08, a current ratio of 3.69 and a quick ratio of 0.90.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings results on Friday, March 27th. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $0.47 million for the quarter, compared to the consensus estimate of $1.35 million. Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%.

Institutional Trading of Humacyte

A number of large investors have recently modified their holdings of HUMA. R Squared Ltd purchased a new position in Humacyte during the 4th quarter worth $25,000. Atom Investors LP bought a new stake in Humacyte during the 4th quarter valued at $25,000. Truist Financial Corp purchased a new stake in shares of Humacyte in the 3rd quarter worth $28,000. Prudential Financial Inc. bought a new position in shares of Humacyte during the 2nd quarter worth $28,000. Finally, Financial Advisors Network Inc. bought a new position in shares of Humacyte during the 2nd quarter worth $28,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.